Inhibition of desipramine hydroxylation (cytochrome P450-2D6)in vitro by quinidine and by viral protease inhibitors: Relation to drug interactions in vivo

Journal of Pharmaceutical Sciences

Volumn 87, Issue 10, 1998, Pages 1184-1189

  Von Moltke, Lisa L ^a,c   Greenblatt, David J ^a   Duan, Su Xiang ^a   Daily, Johanna P ^b   Harmatz, Jerold S ^a   Shader, Richard I ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 ISOENZYME; DESIPRAMINE; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; QUINIDINE; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG HYDROXYLATION; DRUG TRANSFORMATION; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER MICROSOME;

EID: 0031667738     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js980197h     Document Type: Article

References (48)

1. Carpenter, C. C. J.; Fischl, M. A.; Hammer, S. M. et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA Panel. JAMA 1998, 280, 78-86.
2. Barry, M.; Mulcahy, F.; Back D. J. Antiretroviral therapy for patients with HIV disease. Br. J. Clin. Pharmacol. 1998, 45, 221-228.
3. McDonald, C. K.; Kuritzkes, D. R. Human immunodeficiency virus type 1 protease inhibitors. Arch. Intern. Med. 1997, 157, 951-959.
4. Flexner, C. HIV-protease inhibitors. N. Engl. J. Med. 1998, 338, 1281-1292.
5. Barry, M.; Gibbons, S.; Back, D.; Mulcahy, F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin. Pharmacokin. 1997, 32, 194-209.
6. Sahai, J. Risks and synergies from drug interactions. AIDS 1995, 10 (Supp. 1), s21-s25.
7. Merry, C.; Barry, M. G.; Mulcahy, F.; Ryan, M.; Heavey, J.; Tjia, J. F.; Gibbons, S. E.; Breckenridge, A. M.; Back, D. J. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997, 11, F29-F33.
8. Lorenzi, P.; Yerly, S.; Abderrakim, K.; Fathi, M.; Rutschmann, O. T.; von Overbeck, J.; Leduc, D.; Perrin, L.; Hirschel, B. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. AIDS 1997, 11, F95-F99.
9. Kempf, D. J.; Marsh, K. C.; Kumar, G. et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents. Chemother. 1997, 41, 654-660.
10. Wrighton, S. A.; Stevens, J. C. The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 1992, 22, 1-21.
11. Schmider, J,; Greenblatt, D. J.; von Moltke, L. L.; Shader, R. I. Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. J. Clin. Psychopharmacol. 1996, 16, 267-272.
12. Murray, M. P450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease. Clin. Pharmacokin. 1992, 23, 132-146.
13. von Moltke, L. L.; Greenblatt, D. J.; Harmatz, J. S.; Shader, R. I. Cytochromes in psychopharmacology. J. Clin. Psychopharmacol. 1994, 14, 1-4.
14. von Moltke, L. L.; Greenblatt, D. J.; Grassi, J. M.; Granda, B. W.; Duan, S. X.; Fogelman, S. M.; Daily, J. P.; Harmatz, J. S.; Shader, R. I. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J. Clin. Pharmacol. 1998, 38, 106-111.
15. Kumar, G. N.; Rodriguea, A. D.; Buko, A. M.; Denissen, J. F. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 1996, 277, 423-431.
16. von Moltke, L. L.; Greenblatt, D. J.; Cotreau-Bibbo, M. M.; Harmatz, J. S.; Shader, R. I. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br. J. Clin. Pharmacol. 1994, 38, 23-31.
17. von Moltke, L. L.; Greenblatt, D. J.; Cotreau-Bibbo, M. M.; Duan, S. X.; Harmatz, J. S.; Shader, R. I. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J. Pharmacol. Exp. Ther. 1994, 268, 1278-1283.
18. von Moltke, L. L.; Greenblatt, D. J.; Court, M. H.; Duan, S. X.; Harmatz, J. S.; Shader, R. I. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J. Clin. Psychopharmacol. 1995, 15, 125-131.
19. von Moltke, L. L.; Greenblatt, D. J.; Duan, S. X.; Harmatz, J. S.; Shader, R. I. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin-reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J. Clin. Psychopharmacol. 1996, 16, 104-112.
20. von Moltke, L. L.; Greenblatt, D. J.; Duan, S. X.; Harmatz, J. S.; Shader, R. I. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J. Clin. Pharmacol 1994, 34, 1222-1227.
21. von Moltke, L. L.; Greenblatt, D. J.; Schmider, J.; Duan, S. X.; Wright, C. E.; Harmatz, J. S.; Shader R. I. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J. Clin. Pharmacol. 1996, 36, 783-791.
22. von Moltke, L. L.; Greenblatt, D. J.; Harmatz, J. S.; Duan, S. X.; Harrel L. M.; Cotreau-Bibbo, M. M.; Pritchard, G. A.; Wright, C. E.; Shader, R. I. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J. Pharmacol. Exp. Ther. 1996, 276, 370-379.
23. Segel, I. H. Enzyme Kinetics; John Wiley and Sons: New York, 1975.
24. Bertz, R. J.; Cao, G.; Cavanaugh, J. H.; Hsu, A.; Granneman, G. R.; Leonard J. M. Effect of ritonavir on the pharmacokinetics of desipramine. In Proceedings of the International Conference on AIDS, Vancouver, BC, Canada, July 1996; Intercontinental Printing Inc.: Vancouver, BC, Canada; Abstract No. Mo.B.1201.
25. von Moltke, L. L.; Greenblatt, D. J.; Schmider, J.; Wright, C. E.; Harmatz, J. S.; Shader, R. I. In vitro approaches to predicting drug interactions in vivo. Biochem. Pharmacol. 1998, 55, 113-122.
26. von Moltke, L. L,; Greenblatt, D. J.; Schmider, J.; Harmatz, J. S.; Shader, R. I. Metabolism of drugs by Cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin. Pharmacokin. 1995, 29, (suppl 1), 33-43.
27. Greenblatt, D. J.; von Moltke, L. L. Can in vitro models predict drug interactions in vivo? A review of methods, problems, and successes. In Drug-Drug Interactions: Analyzing In Vitro-In Vivo Correlations; Hori, W., Ed.; International Business Communications: Southboro, MA, 1997; pp 2.2.1-2.2.28.
28. Denissen, J. F.; Grabowski, B. A.; Johnson, M. K.; Buko, A. M.; Kempf, D. J.; Thomas, S. B.; Surber, B. W. Metabolism and dispostion of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab. Disp. 1997, 25, 489-501.
29. Brosen, K.; Hansen, J. G.; Nielsen, K.K.; Sindrup, S. H.; Gram, L. F. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur. J. Clin. Pharmacol. 1993, 44, 349-355.
30. Alderman, J.; Preskorn, S. H.; Greenblatt, D. J.; Harrison, W.; Penenberg, D.; Allison, J.; Chung, M. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J. Clin. Psychopharmacol. 1997, 17, 284-291.
31. Preskorn, S. H.; Alderman, J.; Chung, M.; Harrison, W.; Messig, M.; Harris, S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J. Clin. Psychopharmacol. 1994, 14, 90-98.
32. Spina, E.; Gitto, C.; Avenoso, A.; Campo, G. M.; Caputi, A. P.; Perucca, E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur. J. Clin. Pharmacol. 1997, 51, 395-398.
33. Bertilsson, L.; Aberg-Wistedt, A. The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br. J. Clin. Pharmacol. 1983, 15, 388-390.
34. Spina, E.; Birgersson, C.; von Bahr, C.; Ericsson, Ö.; Mellström, B. Steiner, E.; Sjöqvist, F. Phenotypic consistency in hydroxylation of desmethlylimipramine and desbrisoquine in healthy subjects and in human liver microsomes. Clin. Pharmacol. Ther. 1984, 36, 677-682.
35. Brøsen, K.; Gram, L. F. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. Eur. J. Clin. Pharmacol. 1989, 37, 155-160.
36. Steiner, E.; Dumont, E.; Spina, E.; Dahlqvist, R. Inhibiton of desipramine 2-hydroxylation by quinidine and quinine. Clin. Pharmacol. Ther. 1987, 43, 577-581.
37. von Bahr, C.; Spina, E.; Birgersson, C.; Ericsson, T. M.; Göransson, M. Henthorn, T.; Sjöqvist, F. Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem. Pharmacol. 1985, 34, 2501-2505.
38. Otton, S. V.; Crewe, H. K.; Lennard, M. S.; Tucker, G. T.; Woods, H. F. Use of quinidine inhibiton to define the role of the sparteine/debrisoquine Cytochrome P450 in metoprolol oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 1988, 247, 242-247.
39. Yamazaki, H.; Guo, Z.; Persmark, M.; Mimura, M.; Inoue, K.; Guengerich, F. P.; Shimada, T. Bufuralol hydroxylation by Cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol. Pharmacol. 1994, 46, 568-577.
40. Eagling, V. A.; Back, D. J.; Barry, M. G. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br. J. Clin. Pharmacol. 1997, 44, 190-194.
41. Chiba, M.; Hensleigh, M.; Nishime, J. A.; Balani, S. K; Lin J. H. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 1996, 24, 307-314.
42. Chiba, M.; Hensleigh, M.; Lin, J. H. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Biochem. Pharmacol. 1997, 53, 1187-1195.
43. Fitzsimmons, M. E.; Collins, J. M. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4. Drug Metab. Dispos. 1997, 25, 256-266.
44. Bertz, R. J.; Granneman, G. R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokin. 1997, 32, 210-258.
45. Boobis, A. R. Prediction of inhibitory drug-drug interactions by studies in vitro. In Advances in Drug Metabolism in Man; Pacifici, G. M., Fraccia, G. N., Eds.; The European Commission. Luxembourg, 1995; pp 513-539.
46. Leemann, T. D.; Dayer, P. Quantitative prediction of in vivo drug metabolism and interactions from in vitro data. In Advances in Drug Metabolism in Man; Pacifici, G. M., Fraccia, G. N., Eds.; The European Commission. Luxembourg, 1995; pp 783-830.
47. Greenblatt, D. J.; von Moltke, L. L.; Schmider, J.; Harmatz, J. S.; Shader R. I. Inhibition of human Cytochrome P450-3A isoforms by fluoxetine and norfluoxetine; in vitro and in vivo studies. J. Clin. Pharmacol. 1996, 36, 792-798.
48. Obach, R. S. Nonspecific binding to microsomes. Drug Metab. Dispos. 1997, 25, 1359-1369.